Trends and circumstances of pediatric fentanyl deaths in North Carolina: a 10-year retrospective study

Meredith Welch1, Laura W Friederich1, Mary E Cox2

  • 1North Carolina Office of the Chief Medical Examiner, Raleigh, NC 27607, United States.

Insights

Fentanyl deaths in North Carolina children (0-17 years) were analyzed, revealing higher rates in very young children and older adolescents. Key factors included co-sleeping, drug access in homes, and substance use history in older teens.

Area of Science:

  • Forensic Science
  • Public Health
  • Toxicology

Background:

  • Fentanyl overdose deaths are a growing concern among adolescents and children.
  • Understanding the specific circumstances surrounding pediatric fentanyl deaths is crucial for prevention.

Purpose of the Study:

  • To analyze contextual factors and scientific data of fentanyl-related deaths in North Carolina individuals aged 0-17 years from 2015-2024.
  • To identify age-specific trends and risk factors associated with pediatric fentanyl fatalities.

Main Methods:

  • Utilized data from the North Carolina Medical Examiner System (2015-2024).
  • Manually abstracted scene information, toxicology results, and pathological findings for 138 pediatric fentanyl deaths.
  • Analyzed demographic data, overdose onset locations, co-sleeping incidents, substance use history, and postmortem blood fentanyl concentrations.

Main Results:

  • Identified 138 pediatric fentanyl deaths, with higher rates in children under two and adolescents aged 15-17.
  • For children under two, 78.8% of overdoses occurred at home, 60.6% involved co-sleeping in adult beds, and 51.5% had drugs/paraphernalia present.
  • For adolescents, 62.5% of overdoses occurred at home, 82.5% had a history of substance use, and 67.5% had drugs/paraphernalia present.

Conclusions:

  • Specific trends like co-sleeping with drug access in young children and counterfeit pharmaceuticals in adolescents highlight areas for targeted prevention.
  • Age-specific overdose prevention strategies are needed, informed by detailed medicolegal death investigations.
  • Enhanced workflows for pediatric death investigation and electronic reporting are being implemented.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...